To cite this paper use one of the standards below:
Neuropathic pain represents one of the most important types of chronic pain, affecting about 10% of the global population. That condition could be triggered by two main factors: (1) pathology affecting the somatosensorial nervous system and (2) damage caused directly to the central or peripherical nervous system. Known treatments for neuropathic pain are limited and scarce, therefore new pharmacological approaches are required. Preliminary results obtained by Prof. Dr. Thiago Cunha's research group demonstrated that neuropathic pain could be ablated or reduced by tryptophan catabolic pathway inhibition, particularly the kynurenine pathway (kynpath). The first enzyme in kynpath, indoleamine-2,3-dioxygenase 1 (IDO1), compromises the substrate tryptophan into the pathway and is considered a key enzyme to be targeted in the kynpath. We aimed to develop in vitro assays to search for new IDO1 inhibitors, then characterize and improve the molecules, and finally test the selected inhibitors in pre-clinical in vivo models of neuropathic pain. As a result, firstly, IDO1 expression and purification procedures were implemented and validated to obtain the enzyme in the required quantities and high purity. A IDO1 high throughput screening assay was then developed and used to screen 14k chemical samples. Hits were selected and evaluated in concentration-response curves to extract their IC50 values. Forty-five IDO1 inhibitors showed IC50 values below 10 µM. These were further subjected to orthogonal assays, returning 33 confirmed IDO1 inhibitors, 5 have already been confirmed as IDO ligands by STD-fast. The latter molecules belong to five different chemical classes, 2 of which representing novel classes of IDO1 inhibitors. About half of the selected IDO1 inhibitors have already been tested in humans for other applications, 9 are approved drugs. These IDO1 inhibitors represent venues for drug repurposing for chronic pain. In addition, about 35% of the IDO1 inhibitors found are novel bioactive molecules that can be used as basis for innovative drug discovery. The next steps of the project consist of obtaining IDO1 crystallographic complexes with the selected inhibitors, starting from IDO1 apo crystals already acquired at up to 1.9Å resolution. In parallel, the hit series are being expanded and evaluated in structure-activity relationship models along with ADME-Tox evaluation, aiming to select the best hits to progress, or to be optimized, in the pipeline of discovering IDO1 inhibitors for neuropathic pain.
With nearly 200,000 papers published, Galoá empowers scholars to share and discover cutting-edge research through our streamlined and accessible academic publishing platform.
Learn more about our products:
This proceedings is identified by a DOI , for use in citations or bibliographic references. Attention: this is not a DOI for the paper and as such cannot be used in Lattes to identify a particular work.
Check the link "How to cite" in the paper's page, to see how to properly cite the paper